MARS in the treatment of liver failure: Controversies and evidence

被引:11
作者
Chiu, A.
Fan, S. T.
机构
[1] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[2] Queen Mary Hosp, Intens Care Unit, Hong Kong, Hong Kong, Peoples R China
关键词
MARS; albumin dialysis; liver support; liver failure;
D O I
10.1177/039139880602900703
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Molecular Adsorbent Recirculation System (MARS) is a form of extracorporeal detoxification system used as an artificial liver support system. Numerous studies have been published on the topic, with the majority of them describing the capability of MARS in removing albumin-bound toxins and improving systemic hemodynamics. Whether such improvement could be translated into survival benefit is still uncertain, given the paucity of randomized controlled trials available. The outcome of patients receiving MARS treatment is difficult to analyze because liver failure patients constitute a heterogeneous population and different subgroups carry different prognoses. An evidence-based recommendation on the timing of MARS initiation is not available and currently MARS is usually commenced for hyperbilirubinemia or presence of complications of liver failure. MARS is in general a safe procedure, but there are still potential complications that need to be cautioned, along with various operative issues that are worth attention. The future prospects of MARS would rely on the completion of adequately powered randomized controlled trials.
引用
收藏
页码:660 / 667
页数:8
相关论文
共 49 条
[41]   Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure [J].
Sorkine, P ;
Ben Abraham, R ;
Szold, O ;
Biderman, P ;
Kidron, A ;
Merchav, H ;
Brill, S ;
Oren, R .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1332-1336
[42]   Liver support by extracorporeal blood purification:: A clinical observation [J].
Stange, J ;
Mitzner, SR ;
Klammt, S ;
Freytag, J ;
Peszynski, P ;
Loock, J ;
Hickstein, H ;
Korten, G ;
Schmidt, R ;
Hentschel, J ;
Schulz, M ;
Löhr, M ;
Liebe, S ;
Schareck, W ;
Hopt, UT .
LIVER TRANSPLANTATION, 2000, 6 (05) :603-613
[43]  
Stange J, 1999, ARTIF ORGANS, V23, P319
[44]  
Steiner C, 2002, LIVER, V22, P20
[45]   Extracorporal liver support with molecular adsorbents recirculating system in patients with hepatitis B-associated fulminant hepatic failure [J].
Tsai, MH ;
Chen, YC ;
Wu, CS ;
Ho, YP ;
Fang, JT ;
Lien, JM ;
Yang, C ;
Chu, YY ;
Liu, NJ ;
Lin, CH ;
Chiu, CT ;
Chen, PC .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (11) :1289-1294
[46]  
*UN NETW ORG SHAR, 1999, POL 3 6 4 ORG DISTR
[47]   MARS treatment in posthepatectomy liver failure [J].
van de Kerkhove, MP ;
de Jong, KP ;
Rijken, AM ;
de Pont, ACJM ;
van Gulik, TM .
LIVER INTERNATIONAL, 2003, 23 :44-51
[48]   THE CLINICAL IMPORTANCE OF A PROTEIN-BOUND FRACTION OF SERUM BILIRUBIN IN PATIENTS WITH HYPERBILIRUBINEMIA [J].
WEISS, JS ;
GAUTAM, A ;
LAUFF, JJ ;
SUNDBERG, MW ;
JATLOW, P ;
BOYER, JL ;
SELIGSON, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (03) :147-150
[49]  
WILMER A, 2002, LIVER S2, V22, pS52